Drugs in ATC Class M01AE

Up to Top Level ATC Classes

Up to M - Musculo-skeletal system

Up to M01 - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

Up to M01A - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

Drugs in ATC Class: M01AE - Propionic acid derivatives

Tradename	Generic Name
ACETAMINOPHEN AND IBUPROFEN	acetaminophen; ibuprofen
ADVIL DUAL ACTION WITH ACETAMINOPHEN	acetaminophen; ibuprofen
COMBOGESIC	acetaminophen; ibuprofen

M01AE Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class M01AE (Propionic acid derivatives) reveal a complex interplay of growth drivers, competitive pressures, and evolving intellectual property strategies. Here's a synthesis of key findings:

---

Market Dynamics

Market Size and Growth

• The global propionic acid and derivatives market (encompassing pharmaceutical and industrial uses) was valued at $1.11–1.90 billion in 2023–2024 and is projected to reach $1.50–3.05 billion by 2032, with a CAGR of 3.4%–6.10% depending on the segment[[3][8][15][16]].
• Pharmaceutical applications (e.g., NSAIDs like ibuprofen and naproxen) dominate due to their use in treating arthritis, pain, and inflammation, supported by rising chronic disease prevalence[[6][13]].

Key Drivers

1. Expanding Applications:
   • Food preservation: Propionic acid derivatives like calcium propionate prevent mold in baked goods and dairy.
   • Agriculture: Used in animal feed additives and crop protection[[3][15]].
   • Pharmaceuticals: Demand for NSAIDs remains strong, with innovations in formulations (e.g., combinations with proton-pump inhibitors)[[5][6]].
2. Sustainability Trends: Shift toward bio-based production (e.g., fermentation processes) to reduce reliance on petrochemicals[[3][15]].
3. Emerging Markets: Asia-Pacific growth is driven by industrialization and rising healthcare expenditure[[15]].

Challenges

• Generic Competition: Post-patent expiry, generics rapidly erode branded drug revenues. For example:
  • Ibuprofen has 44 branded versions, 228 NDAs, and 238 suppliers globally[[13]].
  • Naproxen sodium faces competition from 129 suppliers and 93 API vendors[[9]].
• Price Pressures: Generics reduce average drug prices by 30–80%, impacting profitability[[11][14]].

---

Patent Landscape

Active Patents and Innovations

• Synthesis Methods: Patents like US5750764A cover novel processes for producing intermediates (e.g., 2-hydroxy-2-(4-isobutylphenyl)propionic acid for ibuprofen)[[2]].
• Formulation Extensions:
  • Combinations (e.g., naproxen + esomeprazole) or pediatric formulations to extend patent life[[5][9]].
  • Polymorphs and Salts: Glaxo’s patents on abacavir hemisulfate and other derivatives highlight strategies to protect niche applications[[7]].

Patent Cliffs

• Over $300 billion in pharmaceutical sales are at risk through 2030 due to expiring patents[[14]].
• Case Study:
  • Naproxen sodium has 6 active U.S. patents but faces generic erosion from 41 applicants and 51 NDAs[[9]].
  • Ibuprofen retains 12 U.S. patents but is widely genericized, with 77 applicants and 228 NDAs[[13]].

Emerging Trends

1. Authorized Generics: Brands minimize revenue loss by licensing generics (e.g., 30% slower share erosion in markets with authorized generics)[[11]].
2. Biologics and Niche Therapies: Companies pivot to complex therapies (e.g., CAR-T for AML) to avoid generic competition[[10][14]].
3. AI-Driven R&D: Focus on improving productivity through gen AI and advanced analytics to accelerate drug discovery[[14]].

---

Strategic Responses

• Mergers & Acquisitions: 77% of biopharma executives expect increased M&A activity to offset patent losses and pipeline gaps[[14]].
• Geographic Diversification: Targeting high-growth regions (e.g., Asia-Pacific) for NSAID demand[[15]].
• Sustainability Initiatives: Bio-based propionic acid production attracts ESG-focused investors[[3][15]].

---

Key Takeaways

• The M01AE drug class faces intense generic competition but benefits from enduring demand in pain management and inflammation.
• Innovation in formulations and strategic IP management (e.g., polymorph patents) are critical for maintaining market share.
• Companies must balance cost pressures with R&D investments in novel therapies and sustainable production methods.

---

“The biopharma industry is facing a substantial loss of exclusivity, with more than US$300 billion in sales at risk through 2030 due to expiring patents.” – Deloitte Insights[[14]]

References

1. http://www.eventiotic.com/eventiotic/files/Papers/URL/ecd717ff-6839-4b01-a64f-d05f52721de1.pdf
2. https://patents.google.com/patent/US5750764A/en
3. https://www.databridgemarketresearch.com/reports/global-propionic-acid-and-derivatives-market
4. https://patents.google.com/patent/US20240306911A1/en
5. https://www.atccode.com/M01AE
6. https://go.drugbank.com/drugs/DB00788
7. http://www.i-mak.org/wp-content/uploads/2017/10/I-MAKHIVDrugPatentsinChinaTahirAminMay2010.pdf
8. https://www.researchandmarkets.com/reports/5948843/propionic-acid-market-report
9. https://www.drugpatentwatch.com/p/generic-api/naproxen+sodium
10. https://www.delveinsight.com/blog/acute-myeloid-leukemia-aml-market-insights-epidemiology-and-market-forecast-2020
11. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3450773
12. https://go.drugbank.com/drugs/DB00991
13. https://www.drugpatentwatch.com/p/generic/ibuprofen
14. https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-life-sciences-executive-outlook.html
15. https://pmarketresearch.com/product/worldwide-bee-glue-market-research-2024-by-type-application-participants-and-countries-forecast-to-2030/worldwide-propionic-acid-and-derivatives-market-research-2024-by-type-application-participants-and-countries-forecast-to-2030
16. https://introspectivemarketresearch.com/reports/propionic-acid-and-derivatives-market/